Omron Healthcare has launched a 24,000-square-metre manufacturing facility near Chennai, aiming to produce 3 million blood pressure monitors annually by 2028. The plant will initially focus on India's domestic market, where low penetration of home diagnostic devices presents a growth opportunity. This move aligns with India's push to become a hub for medical device manufacturing.
Omron Healthcare has officially started full-scale production at its first manufacturing facility in India, located near Chennai. The 24,000-square-metre plant is a key step for the Kyoto-based company to localise its supply chain. The company has set a target to produce 3 million blood pressure monitors annually by 2028 to serve the Indian market.
For the immediate future, the facility will focus entirely on supplying the domestic market. India currently faces a significant health challenge with high rates of hypertension, yet the usage of home blood pressure monitoring devices remains low at less than 5% of households. Omron Healthcare, which held a 40% share of this segment in India in 2025, intends to use this facility to bridge the gap between high prevalence and low diagnostic access. By assembling locally, the company aims to improve product availability and reduce reliance on imported finished goods.
The strategic shift toward local manufacturing aligns with the government's Make in India initiative. Historically, a large portion of medical devices used in India has been imported. While the current facility uses assembly technologies and quality-control standards from Omron’s operations in Japan and Vietnam, the long-term objective is to deepen the localization of parts. This would help the company manage logistical costs and reduce dependence on external supply networks.
While this facility aims to serve the domestic market, the company has indicated plans to eventually transform the Chennai site into an export hub. However, for the Indian medical device sector, the focus on local manufacturing is critical. The sector is currently seeing increased interest as manufacturers try to mitigate risks related to global supply chain disruptions and volatile shipping costs. Indian medical device companies and subsidiaries are increasingly looking to establish domestic production to lower their import bill and gain better control over quality and distribution.
Investors and market watchers should note that the success of such initiatives depends on several factors beyond initial capacity. The ability to source raw materials locally without compromising quality standards is a key challenge for medical device makers in India. Additionally, the company will face stiff competition in the domestic market, as price-sensitive consumers often choose lower-cost diagnostic options. As Omron scales its operations, key monitorables include the percentage of components sourced domestically, the ability to maintain profit margins amid local competition, and the actual pace of demand growth for home healthcare devices across India.